Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02278133 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | PHASE1 | COMPLETED | 20 | — | — | Dec 1, 2014 | Jun 23, 2017 | Oct 9, 2017 | 19 | United States, Australia +8 |
Phase Ib: To estimate the MTD(s) and/or RP2D(s) of the triple combination of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant, KRAS wild-type (WT) mCRC harboring upstream Wnt pathway mutations.
Phase II: To estimate the preliminary anti-tumor activity of the RP2D(s) of the combination of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant metastatic CRC harboring upstream Wnt pathway mutations
| Arm | Type | Description |
|---|---|---|
| WNT974, LGX818 and cetuximab combo | EXPERIMENTAL | Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab |
| Name | Type | Description |
|---|---|---|
| WNT974 | DRUG | - |
| LGX818 | DRUG | - |
| Cetuximab | BIOLOGICAL | - |
Inclusion Criteria: * Male or female aged ≥ 18 years * Histological or cytological confirmed metastatic colorectal cancer * Written documentation of KRAS wild-type status and BRAFV600-mutation with RNF43 mutation and/or RSPO fusion * Progression of disease after at least one prior standard of care ...